Form 4: SGMO CEO Macrae Reports RSU Vesting & Tax Withholding

Sangamo Therapeutics CEO Sandy Macrae disposed of 126,950 shares of common stock for mandatory tax withholding purposes following an RSU vesting event.

Summary

• Sandy Macrae, President, CEO, and Director of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on October 22, 2025.
• The transaction involved the disposition of 126,950 shares of common stock.
• This disposition was solely for mandatory tax withholding purposes, utilizing the Issuer's closing stock price of $0.66 per share on October 22, 2025.
• The shares were surrendered in connection with the vesting of a portion of a Restricted Stock Unit (RSU) grant, as per the company's Amended and Restated 2018 Equity Incentive Plan.
• This was a non-discretionary transaction by the Reporting Person.
• Following this transaction, Macrae beneficially owns 2,057,022 shares of common stock.
• The beneficially owned shares include 123,050 shares from a January 22, 2024 RSU grant (with remaining 250,000 shares vesting quarterly through January 22, 2026).
• Also included are 29,494 shares from a February 24, 2023 RSU grant (vesting quarterly through February 24, 2026).
• Additionally, 375,000 shares from a February 25, 2025 RSU grant are included, with one-fourth vesting on February 25, 2026, and the remainder in 8 successive equal quarterly installments.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding related to RSU vesting, which is a neutral event from an investment sentiment perspective.

Positives

• The underlying event was the vesting of Restricted Stock Units (RSUs), which represents earned equity compensation for the CEO.

Future Outlook

Future vesting installments for various Restricted Stock Unit (RSU) grants are scheduled through January 22, 2026, February 24, 2026, and in successive quarterly installments following February 25, 2026, subject to the Reporting Person's continuous service.

Industry Context

This filing is a routine insider transaction report related to executive compensation and does not provide information directly related to broader industry trends or competitors.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale indicating a change in management's investment sentiment.
• Employees (Executive): The vesting of RSUs represents a realization of compensation, which is a positive for the executive.

Next Steps

• Continued vesting of remaining RSU grants for Sandy Macrae according to the established schedules through January 22, 2026, February 24, 2026, and subsequent quarterly installments following February 25, 2026.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Tax Withholding, Equity Compensation, Sandy Macrae